Acuta Capital Partners LLC Has $4.25 Million Holdings in argenx SE (NASDAQ:ARGX)

Acuta Capital Partners LLC raised its position in argenx SE (NASDAQ:ARGX - Free Report) by 17.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,910 shares of the company's stock after acquiring an additional 1,010 shares during the quarter. argenx makes up 4.3% of Acuta Capital Partners LLC's investment portfolio, making the stock its 9th largest position. Acuta Capital Partners LLC's holdings in argenx were worth $4,250,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of ARGX. GeoWealth Management LLC lifted its holdings in argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares during the period. Whipplewood Advisors LLC purchased a new stake in shares of argenx in the 4th quarter worth about $37,000. Global Retirement Partners LLC boosted its position in argenx by 369.2% during the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock valued at $38,000 after acquiring an additional 48 shares in the last quarter. FIL Ltd bought a new position in shares of argenx in the 4th quarter worth approximately $38,000. Finally, Jones Financial Companies Lllp lifted its stake in shares of argenx by 1,016.7% in the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after purchasing an additional 61 shares during the period. 60.32% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ARGX has been the topic of a number of recent research reports. Sanford C. Bernstein raised shares of argenx from a "market perform" rating to an "outperform" rating in a research report on Monday, March 17th. Citigroup upped their price target on shares of argenx from $681.00 to $796.00 and gave the stock a "buy" rating in a research note on Thursday, April 17th. Piper Sandler increased their price objective on shares of argenx from $620.00 to $725.00 and gave the company an "overweight" rating in a research report on Tuesday, January 7th. HC Wainwright reaffirmed a "buy" rating and issued a $720.00 target price on shares of argenx in a report on Tuesday, April 8th. Finally, Wells Fargo & Company increased their price target on shares of argenx from $723.00 to $741.00 and gave the company an "overweight" rating in a report on Friday, February 28th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $699.28.

argenx Trading Down 0.8 %

argenx stock opened at $639.90 on Friday. argenx SE has a 12-month low of $352.77 and a 12-month high of $678.21. The firm has a market capitalization of $39.07 billion, a price-to-earnings ratio of -727.16 and a beta of 0.60. The firm has a 50 day moving average of $597.82 and a 200 day moving average of $610.65.

argenx (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The firm had revenue of $761.22 million during the quarter, compared to analysts' expectations of $678.52 million. On average, analysts predict that argenx SE will post 3.13 EPS for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.